Navigation Links
Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
Date:2/3/2009

ST. LOUIS, Feb. 3 /PRNewswire/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of prescription prenatal and iron supplement nutritionals as identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medication may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

    Products Recalled to the Wholesale Level:

    Prescription Iron Supplement Products:

    Chromagen(R) Caplet                     Chromagen(R) FA Caplet
    Chromagen(R) Forte Caplet               Encora(R) Capsule
    Niferex(R) Gold Tablet                  Niferex(R) 150 Forte Capsule
    Repliva 21/7(R) Tablet

    Prescription Prenatal Vitamin Products:

    PreCare(R) Chewable Tablet              PreCare(R) Conceive Tablet
    PreCare Premier(R) Tablet               PremesisRx(R) Tablet
    PrimaCare(R) Capsule/Tablet             PrimaCare(R) Advantage(TM)
    PrimaCare(R) ONE Capsule                 Capsule/Tablet

Any retail customer inquiries related to this action should be addressed to Ther-Rx Customer Service at 877-567-7676, or faxed to Ther-Rx Customer Service at (314) 646-3701, or e-mailed to info@ther-rx.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

Ther-Rx Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products. Patients with questions about the recall should call the telephone number above, or contact their healthcare providers.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Any adverse reactions experienced with the use of these products should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE Ther-Rx Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... The International Essential Tremor Foundation (IETF) will host ... tremor (ET). The seminar will take place on Saturday, Aug. 26 at the Embassy ... program will run from 9 a.m. to 12 p.m., with check-in beginning at 8 ...
(Date:7/24/2017)... ... July 24, 2017 , ... Axiad IDS , a leading provider of ... with WALLIX to expand its solution to help government contractors more quickly ... number of ways to address the authentication requirements within NIST SP800-171, but no ...
(Date:7/24/2017)... ... , ... Independence Blue Cross (Independence) and ... program, have signed a five-year agreement that will marshal resources from both organizations ... patients receive. The agreement also signifies Jefferson Health officially joining the Independence ...
(Date:7/24/2017)... California (PRWEB) , ... July 24, 2017 , ... ... of autologous fat (adipose) transfer systems announces the issuance of United States Patent ... patent) for its adipose filtration technology. The '398 and '324 patents cover ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... National Harbor, MD. This year's theme focuses on the new ISO/IEC 17025 standards. ... quality and integrity in testing and calibration will be changed. , As ...
Breaking Medicine News(10 mins):
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/15/2017)... 15, 2017 Enterin Inc., a Philadelphia ... disease (PD), today announced the completion of a $12.7 million ... Ventures III, as well as the participation of existing investors. ... to have the support of New Ventures III and our ... validation of the potential of our platform technology to transform ...
(Date:7/13/2017)... Medical Products, a leader in medical product innovation and global patient ... for hospice patient care. ... Centurion Medical Products ... pain management and emotional comfort are part of a hospice,s primary ... preventing unneeded emergency department admission due to severe fecal impaction. One ...
Breaking Medicine Technology: